← all signals · sectors · research
Intellia Therapeutics, Inc. NTLA
SIC 2835 — In Vitro & In Vivo Diagnostic Substances · CIK 1652130
This page lists every Interactive Market Data signal that fired on this company across fiscal years, with the calibrated net-of-cost forward-return prediction. Predictions use a triple → pair → singles fallback against our backtest panel (~32K (cik × fy) signal combos, net of execution costs at 5 bps half-spread + ADV-tiered borrow).
FY2023 short
1 signal fired ·
match: singles_avg
| Horizon | Predicted net PnL |
|---|---|
| 20 days | -2.54% |
| 60 days | -11.34% |
| 252 days (1y) | -24.65% |
FY2021 short
2 signals fired ·
match: pair
| Horizon | Predicted net PnL |
|---|---|
| 20 days | +2.99% |
| 60 days | -0.67% |
| 252 days (1y) | -33.05% |
FY2017 short
1 signal fired ·
match: singles_avg
| Horizon | Predicted net PnL |
|---|---|
| 20 days | +1.36% |
| 60 days | -1.61% |
| 252 days (1y) | -16.85% |
Methodology: /methodology · Live JSON: /api/company/1652130/financials